1. Global revolution in cancer biomarkers real-time diagnostics
inPROBE
Global revolution in cancer biomarkers real-time diagnostics
December 2018
Disruptive innovation co-funded by Horizon2020

2. CANCER Diagnostics – Global Society Health Challange
Major FACTS on Cancer
Fact
There are more than 100 types of cancers; any part of the body can be affected.
8.2 milion people die each year from cancer, an estimated 13% of all deaths worldwide ( women die of breast cancer every single year)
70% the increase in new cases of cancer expected over the next 2 decades (from 14 milion in 2012)
>100 cancer types exist, each requiring unique diagnosis and treatment.
Fact
Worldwide, the 5 most common types of cancer that kill men are (in order of frequency): lung, stomach, liver, colorectal and esophagus.
Fact
Worldwide, the 5 most common types of cancer that kill women are (in the order of frequency): breast, lung, stomach, colorectal and cervical. In many developing countries, cervical cancer is the most common cancer.
Fact
Tobacco use is the single largest preventable cause of cancer in the world causing 22% of cancer deaths
Fact
Cancers of major public health relevance such as breast, cervical and colorectal cancer can be cured if detected early and treated adequately.
Source: World Health Organization
Fact
Average age of Pathologists in Europe has just exceeded 60 years of age and there is a dramatic small income of young physicians into this medical area.
This will create a huge burden in the future of histopathology diagnostics

3. EARLY STAGE CANCER DIAGNOSTICS IS KEY TO CURE
Acc. to WHO there are three steps to cancer early diagnosis and bariers around them
Building diagnostic capacity and improving referral mechanisms can overcome common barriers to timely diagnosis. Health-care providers at all levels of care should be equipped with the skills to identify cancer symptoms and perform or refer for diagnostic tests. Pathology is particularly important in cancer diagnosis.

4. inPROBE by SDS OPTIC – breakthrough in cancer biomarkers diagnostics

5. Our solution for global society health challange
inPROBE, invented and developed by SDS Optic, is cancer diagnostic device, designed to reduce time of cancer biomarkers diagnosis, increase precision and effects of advanced cancer treatments. It has global potential to replace current histophatology cancer diagnostics with possible far less-invasive substitution to the traditional biopsies
InProbe is a nano-size glass probe getting in vivo connected with detecting device and with innovative biotech components at the tip of the probe, merging cancer biology, chemistry and optoelectronics. Thanks to its thicknes it is safer, much less stressful and much less painful for Patients.
inPROBE will shorten the tumor marker testing from several days or weeks to several minutes, without painfull tissue biopsy and laboratory involvment
inPROBE combines traditional biopsy and histopathology (f.e. FISH or IHC as current gold standards) and contains innovative components secured with PCT patent application (patent pending)
Real-Time tumor markers diagnostics CAN BE a complete groundbreaking milestone in fighting cancer as it can allow immediete launch of targeted treatment (f.e. Herceptin, Avastin, Erbitux).
This can lead to saving 30% people diagnosed with cancer as World Health Organization states that „Cancer can be cured if detected early”
inPROBE technology can be easily scaled-up for all types of cancer, infectious diseases, treatment monitoring and paired with other medical diagnostic devices (f.e. endoscopy) can lead to brand new breakthrough screening technology by adding real-time biology testing possible during endoscopy/imaging diagnostics

6. Revolution in cancer diagnosis – key benefits of our core technology
In-vivo examination and real time results
We don’t intend to take any tissue biopsy, we measure in-vivo and in real-time (15-20 mins)
High Sensitivity
In many cases our technology allows to perform test without tumor infraction (f.e. at HER2+ breast cancer) which is important in terms of tumor damage effects. We may perform tests close to the tumor.
Today cancer can be detected from blood (f.e. ELISA tests, modern liquid biopsies) but it means it has been detected very late and cancer has very advanced stadium. Those technologies will not detect cancer at early stage
Our technology, linked with endoscopy, can detect cancer at very early stage during the endoscopy screening tests. This applies f.e. at Colorectal, Stomach, Oesophagus cancers.
Objective results
We deliver numerical results.
Today pathology results are not numerical, are based on pathologist experience and equipment available
Patients wellbeing
Real-time diagnosis give opportunity to immediately introduce treatment. No waiting time (often many weeks)
Numerous possibilities (scale-up)
Most types of cancer markers, pre-cancer screening (infectious & bacterial diseases)

7. ABOUT US

8. ABOUT US – HOW WE GET HERE

9. ABOUT US – CORE TEAM

10. ABOUT US – OUR R&D ASSETS

11. Who trusted us?

12. More details
Follow us at:

13. Thank you SDS OPTIC LLC Konstantynow 1F, 20-708 Lublin , POLAND
office (+48)